SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 28, 2002
Inamed Corporation
- -------------------------------------------------------------------------------
(Exact name of registrants as specified in their charter)
Delaware 1-9741 59-0920629
- -------------------------------------------------------------------------------
(State or other jurisdiction (Commission File Number) (IRS Employer of
incorporation) Identification No.)
5540 Ekwill Street, Suite D, Santa Barbara, California 93111
- -------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrants' telephone number including area code: (805) 692-5400
(Former name or former address, if changed since last report.) Not applicable.
ITEM 9. REGULATION FD DISCLOSURE.
On January 28, 2002, Inamed Corporation ("Inamed") announced
unaudited sales results for 2001 and a regulatory update. A copy of the press
release announcing the same is attached as Exhibit 99.1 to this Current Report
on Form 8-K.
Nick Teti, Inamed's President and CEO, will be presenting at the
U.S. Bancorp Piper Jaffrey Health Care Conference on Tuesday, January 29th,
at 3:30 p.m. EST. Mr. Teti is expected to discuss the performance of the
Company's portfolio and its pipeline of future products. As announced in the
attached press release, the webcast of the call (live and replay) is
accessible on
http://www.on24.com/clients/piperjaffray/conference_020129/index.html?presenter=
inamedcorpo&format=rmmulti. Listeners should go to the website at least 15
minutes early to register and download and install any necessary audio software.
A copy of the presentation will be also be available on the Inamed Corporation
website, http://www.inamedcorp.com.
Inamed will report fourth quarter and full year 2001 results after
the market closes on Thursday, February 7, 2002. The Company will host a
conference call that same day at 5:00 p.m. EST. Investors can access the
conference call in the U.S. by dialing (800) 865-4460, international callers,
dial (973) 628-9554, then in either case, asking to be connected to the Inamed
investor call. Individuals and media can also access the conference call via the
Internet through Investor Broadcast Network's Vcall Web site, www.vcall.com. To
listen, go to the Web site at least 15 minutes early to register and download
and install any necessary audio software. For those unable to participate, a
rebroadcast will be made available through Vcall's Web site for 30 days after
the call. It will be available shortly after the call.
FORWARD LOOKING STATEMENTS WARNING
- ----------------------------------
This Current Report on Form 8-K contains projections and other
forward-looking statements that involve risks and uncertainties. These
statements may differ materially from actual future events or results. Readers
are referred to the documents filed by Inamed Corporation with the Securities
and Exchange Commission, specifically the most recent reports which identify
important risk factors that could cause actual results to differ from those
contained in the forward-looking statements, including but not limited to:
exposure to product liability claims; exposure to liabilities that may not be
adequately covered by insurance; potential negative publicity concerning product
safety; potential fluctuations in quarterly results; volatility of Inamed's
stock price; changes in the economy and consumer spending; uncertainty in
receiving timely regulatory approval or market acceptance for new products;
dependence on a single supplier for each of Inamed's silicone raw materials and
bovine collagen-based products; and adverse changes in the regulatory or
legislative environment (both in the U.S. and internationally) affecting our
business. The information contained in this Current Report on Form 8-K is a
statement of Inamed's present intention, belief or expectation and is based
upon, among other things, the existing regulatory environment, industry
conditions, market conditions and prices, the economy in general and Inamed's
assumptions. Inamed may change its intention, belief or expectation, at any time
and without notice, based upon any changes in such factors, in Inamed's
assumptions or otherwise. Inamed undertakes no obligation to review or confirm
analysts' expectations or estimates or to release publicly any revisions to any
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.
By including any information in this Current Report on Form 8-K,
Inamed does not necessarily acknowledge that disclosure of such information is
required by applicable law or that the information is material.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
Exhibit 99.1 Press Release dated January 28, 2002.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INAMED CORPORATION
/S/ DAVID BAMBERGER
By: David Bamberger, General Counsel
DATED: January 28, 2002